Statement from Sung Poblete, PhD, RN, CEO of FARE on EURneffy Adrenaline Nasal Spray, Recommended for Approval in the EU
"Today, epinephrine nasal spray, EURneffy, was recommended for approval in the EU. FARE is pleased to share this news because a needle-free method for epinephrine delivery is a huge win for the food allergy community. The more than 33 million people in the U.S. with the disease of food allergy are anxious to have the same choices for epinephrine delivery. We celebrate this win for the food allergy community in the EU and we hope to be able to celebrate neffy's availability in the U.S. very soon, because patients can't wait for this life-saving treatment option."
Media Contact:
About FARE
FARE (Food Allergy Research & Education) is the nation’s leading non-profit engaged in food allergy advocacy and the largest food allergy charity supporting research. FARE’s innovative education, advocacy and research initiatives transform the future of food allergy through new and improved treatments and prevention strategies, effective policies and legislation, and novel approaches to managing the disease. To learn more, visit: foodallergy.org.